6 results about "Regadenoson" patented technology

This invention provides a method for detecting related substances in Reganosine starting materials. The method is a high-performance liquid chromatography (HPLC) method. The related substances include residual impurities in the starting materials, process by-product impurities, and diastereomers of the Reganosine starting materials. The chromatographic conditions are: mobile phase A: aqueous acetic acid; mobile phase B: methanol; gradient elution. The method provided by this invention can effectively separate 2-chloroadenosine and its impurities. Furthermore, studies on the specificity, accuracy, precision, limit of detection, limit of quantitation, linear range, and robustness of the method demonstrate that this detection method has high specificity and high sensitivity.

The application discloses a pharmaceutical equipment and method for regadenoson injection and the medicine thereof, and particularly relates to the technical field of the pharmaceutical equipment for regadenoson injection, and comprises the manufacturing pharmaceutical equipment and the injection. The knocking device is arranged, and the impurities adhered to the inner wall of the feeding hopper are not easy to be accumulated to cause the blockage of the discharge port of the feeding hopper and affect the later filtering through the continuous knocking of the knocking rod. In addition, the injection is a colorless and transparent liquid, the pH value is 3.9-5.0, and the content of regadenoson is 93.0%-103.0% of the marked amount.

The invention discloses a nuclear medicine imaging technology-based evaluation method for treating myocardial microvascular diseases by using mesenchymal stem cell exosomes, and relates to the technical field of cardiovascular disease diagnosis. The method comprises the following steps that 1, after a microsphere embolism method is used for modeling, 18F-Flurridaz microPET / CT is used for conducting resting state imaging and Regadenoson load state imaging, Pmod software is used for analysis to obtain myocardial coronary artery blood flow reserve (CFR) of a model mouse, and the myocardial microvessel blood perfusion injury degree is determined; 2, after sequential treatment is carried out through exosomes of the mesenchymal stem cells, a 18F-FDG tracer agent is regularly injected in an intravenous mode, microPET / CT scanning is carried out, and metabolism imaging data of the cardiac muscle of the model mouse is obtained; 3, after scanning, PMOD software is used for processing imaging data, a myocardial bullseye map is generated, the myocardial bullseye map can display metabolism conditions of all segments of the myocardium, and by comparing metabolism values before and after treatment, the metabolism improvement effect of treatment on all the segments of the myocardium is analyzed, and the influence of treatment on myocardial energy metabolism recovery is revealed.

The utility model discloses an extraction mechanism for Regadenoson injection preparation, which comprises a mixing box, the mixing box is provided with a stirring mechanism and a circulating mechanism, the stirring mechanism comprises a stirring assembly, the stirring assembly comprises a support, the support is fixedly installed on the side face of the mixing box, the top end of the support is fixedly provided with a vertical plate, and the vertical plate is fixedly installed on the side face of the mixing box. A first motor is fixedly installed on the side face of the vertical plate, the rotating shaft end of the first motor penetrates through the vertical plate and is fixedly provided with a rotating disc, a sliding rod is fixedly installed on the rotating disc, a limiting plate is fixedly installed on the side face of the vertical plate, and a lifting rod penetrates through the limiting plate in a sliding mode. By arranging the stirring mechanism, molecular diffusion between a to-be-separated solution and an extraction solution can be accelerated, so that the to-be-separated solution and the extraction solution reach a more uniform mixing state in a short time, the speed and the efficiency of the extraction process are improved, and meanwhile, the extraction solution is favorably ensured to be uniformly distributed in the whole to-be-separated solution through stirring; and the condition that the local concentration is too high or too low is avoided.

The utility model discloses a regadenoson injection stirring device with nitrogen protection, which comprises a stirring barrel, the stirring barrel is fixed on a base, an upper cover is hermetically arranged at an opening at the upper end of the stirring barrel through threads, the upper cover is provided with a motor, the output end of the motor is connected with a rotating shaft, and the rotating shaft is provided with a stirring rod in the stirring barrel. A rotating seat and an adjusting seat are arranged on the two sides of the stirring barrel respectively, the rotating seat is connected with a gas conveying pipe, the gas conveying pipe is connected with an external nitrogen pump, the adjusting seat is connected with a liquid conveying pipe and provided with a plugging block through a closed structure, a closed seat is arranged at the bottom of the stirring barrel and connected with a liquid outlet pipe, and a rubber valve is arranged at the position, located at the joint of the closed seat, of the liquid outlet pipe. A valve is arranged at the other end of the sealing seat. The regadenoson injection mixing device is simple in structure, regadenoson injection is rapidly mixed through the stirring mechanism, airflow is mixed in the solution by filling nitrogen into the regadenoson injection mixing device so as to accelerate the reaction speed, and the stirring mechanism is integrally closed, convenient to control, high in practicability and suitable for popularization.

A use of regadenoson in the preparation of a drug for detecting a cardiac ischemic disease in echocardiography. The echocardiography is selected from one or more of stress echocardiography, myocardial contrast echocardiography, transthoracic Doppler echocardiography, and two-dimensional speckle tracking echocardiography. The cardiac ischemic disease is selected from one or more of a non-obstructive cardiac ischemic disease or an obstructive cardiac ischemic disease. By administering the drug, diagnosis of the disease in a patient exhibits good accuracy, sensitivity, specificity, and safety.